Medical Imaging
Integrated solutions based on the science of imaging biomarkers
Improving decision making, increasing efficiency and potentially reducing trial costs
-
1,534
Clinical trials -
341,544
Subjects -
73,427
Sites
Medical imaging endpoints can provide objective evidence of a drug’s safety and efficacy across all phases of development. ICON provides end-to-end integrated solutions based on the science of imaging biomarkers via cutting edge technology and image analysis tools. Our use of leading-edge technology combined with market leading expertise and best practice processes streamline the collection and management of images during clinical trials.
As experts in medical imaging and cardiac safety testing for clinical trials, we provide the ideal combination of personal service, global reach, scientific expertise, and on-time data delivery. Our core team of more than 450 qualified clinical imaging professionals includes radiologists, imaging scientists, and certified imaging technologists. These highly trained and experienced experts will provide advice on imaging endpoints and the critical uses of imaging for the medical, scientific and regulatory aspects of your trial - enabling improved clinical trial decision making and successful outcomes.
As part of one of the world's largest global CRO’s we have access to a wealth of operational and scientific resources. When you partner with ICON you will benefit from:
-
Access to a network of 1200+ highly trained radiologists, certified in their modalities, and experienced in how to view and improve image quality
-
The highest quality reader model in the industry – consistently delivering reader performance metrics beyond our competitors
-
A global network using standard processes to deliver consistent, reproducible quality data
- Oncology Experts in the complex world of clinical trial oncology response criteria implementation
- Cardiovascular Experience in all cardiovascular indications and imaging modalities
- Central nervous system Clinical trial imaging study experience across a variety of central nervous system diseases
- MASLD/MASH and metabolic imaging Multi-modal image acquisition and processing expertise in MASH and obesity assessments
- Collect and hold Collect and hold in early phase imaging clinical trials
- Rescue studies Seamless take over and delivery of image analysis results according to your trial schedule.
- Technology platforms Leading edge technology to streamline the collection, management and analysis of images during clinical trials.
Oncology
Experts in the complex world of clinical trial oncology response criteria implementation
Cardiovascular
Experience in all cardiovascular indications and imaging modalities
Central nervous system
Clinical trial imaging study experience across a variety of central nervous system diseases
MASLD/MASH and metabolic imaging
Multi-modal image acquisition and processing expertise in MASH and obesity assessments
Collect and hold
Collect and hold in early phase imaging clinical trials
Rescue studies
Seamless take over and delivery of image analysis results according to your trial schedule.
Technology platforms
Leading edge technology to streamline the collection, management and analysis of images during clinical trials.
End-to-end support for all critical components of your imaging study:
|
|
|
Advances in imaging biomarkers: Estimating drug efficacy with tumour growth rate modelling
This whitepaper compares the use of imaging biomarker methodologies such as RECIST 1.1 with novel tumour growth rate (TGR) modelling. Using this methodology eliminates the need for a comparable control arm which can reduce research costs. TGR modelling also more efficiently captures heterogeneous tumour measurements and whole-body tumour burden.
Find out more:
Discover how ICON Medical Imaging can improve decision making, increase efficiency and potentially reduce costs within your clinical trials.